A new pacemaker algorithm for the treatment of atrial fibrillation Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT) by Carlson, Mark D et al.
A New Pacemaker Algorithm
for the Treatment of Atrial Fibrillation
Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT)
Mark D. Carlson, MD, MA,* John Ip, MD,† John Messenger, MD,‡ Scott Beau, MD,§
Steven Kalbfleisch, MD, Pierre Gervais, MD,¶ Douglas A. Cameron, MD,# Aurelio Duran, MD,**
Jesus Val-Mejias, MD,†† Judith Mackall, MD,* Michael Gold, MD, PHD,‡‡ for the ADOPT Investigators
Cleveland and Columbus, Ohio; Lansing, Michigan; Long Beach, California; Little Rock, Arkansas; Trois-Rivieres
and Toronto, Canada; Orlando, Florida; Wichita, Kansas; and Charleston, South Carolina
OBJECTIVES The Atrial Dynamic Overdrive Pacing Trial (ADOPT) was a single blind, randomized,
controlled study to evaluate the efficacy and safety of the atrial fibrillation (AF) Suppression
Algorithm (St. Jude Medical Cardiac Rhythm Management Division, Sylmar, California) in
patients with sick sinus syndrome and AF.
BACKGROUND This algorithm increases the pacing rate when the native rhythm emerges and periodically
reduces the rate to search for intrinsic atrial activity.
METHODS Symptomatic AF burden (percentage of days during which symptomatic AF occurred) was
the primary end point. Patients underwent pacemaker implantation, were randomized to
DDDR with the algorithm on (treatment) or off (control), and were followed for six months.
RESULTS Baseline characteristics and antiarrhythmic drugs used were similar in both groups. The
percentage of atrial pacing was higher in the treatment group (92.9% vs. 67.9%, p  0.0001).
The AF Suppression Algorithm reduced symptomatic AF burden by 25% (2.50% control vs.
1.87% treatment). Atrial fibrillation burden decreased progressively in both groups but was
lower in the treatment group at each follow-up visit (one, three, and six months) (p 0.005).
Quality of life scores improved in both groups. The mean number of AF episodes (4.3 11.5
control vs. 3.2  8.6 treatment); total hospitalizations (17 control vs. 15 treatment); and
incidence of complications, adverse events, and deaths were not statistically different between
groups.
CONCLUSIONS The ADOPT demonstrated that overdrive atrial pacing with the AF Suppression Algorithm
decreased symptomatic AF burden significantly in patients with sick sinus syndrome and AF.
The decrease in relative AF burden was substantial (25%), although the absolute difference
was small (2.50% control vs. 1.87% treatment). (J Am Coll Cardiol 2003;42:627–33)
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Atrial fibrillation (AF) affects an estimated 2.3 million indi-
viduals, causes significant morbidity, and is associated with
$1 billion in health costs each year in the U.S. (1). Despite the
development and use of class IC and class III antiarrhythmic
drugs, AF recurs in many patients (2). Furthermore, antiar-
rhythmic drugs are associated with side effects that may
increase mortality or require that therapy be terminated.
Previous studies suggested that dual-chamber or atrial
pacing decreases the risk for AF in patients who require
permanent pacing for sinus node dysfunction (3,4). Poten-
tial mechanisms responsible for an antiarrhythmic effect
attributed to atrial pacing include rate dependent effects on
refractoriness, reduction of ectopy, prevention of pauses,
and remodeling of the electrophysiologic substrate.
A new rate adaptive atrial pacing algorithm (AF Suppres-
sion Algorithm, St. Jude Medical Cardiac Rhythm Man-
agement Division, Sylmar, California) was designed to
provide a high percentage of atrial paced beats while
allowing for the normal diurnal variation in the heart rate.
The algorithm increases the pacing rate when the native
rhythm emerges and periodically reduces the rate gradually
to search for intrinsic atrial activity. The Atrial Dynamic
Overdrive Pacing Trial (ADOPT) was designed to assess
the clinical efficacy and safety of the AF Suppression
Algorithm in patients with AF, sick sinus syndrome, and an
indication for permanent pacing. The primary objectives
were to determine whether the algorithm in combination
with DDDR pacing is safe and effective in reducing symp-
tomatic AF compared with DDDR pacing alone.
METHODS
General. The ADOPT was a single blind, prospective, con-
trolled, multicenter, randomized clinical trial. Patients were
enrolled between December 11, 1998 and December 31, 2000.
Patient selection. The principal inclusion criteria were: 1)
symptomatic paroxysmal or persistent AF with at least two
symptomatic episodes in the month preceding implant on a
stable antiarrhythmic drug and/or atrioventricular nodal
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blocking agent (or no drugs) and at least one episode in the
12 weeks preceding implant documented by electrocardio-
gram (ECG) or rhythm strip; 2) sinus node dysfunction
with a 1998 American College of Cardiology/American
Heart Association class 1 bradycardia indication for a
dual-chamber pacemaker (5); and 3) written informed
consent for participation and willingness and ability to
comply with follow-up testing and evaluation procedures.
The protocol was reviewed and approved by the institutional
review board of each participating center. The principal
exclusion criteria were presence of another arrhythmia
control device, cardiac surgery in the last six months, or
expected cardiac surgery during the six-month study period.
Atrial fibrillation was defined as a minimum of 30 s of
continuous irregular ECG baseline with no discrete P waves
and variable R-R intervals. Paroxysmal AF was defined as
an episode of AF that terminates spontaneously. Persistent
AF was defined as that which required cardioversion to
restore normal sinus or paced atrial rhythm after at least
24 h of continuous arrhythmia.
Patient history, implantation, and follow-up. Pre-
implant assessment consisted of medical history, physical
examination, 12-lead ECG and quality of life assessment.
Randomization was conducted via sequentially numbered
sealed envelopes that were distributed to and maintained by
each investigational center. Each envelope was opened sequen-
tially, and contained the patient’s treatment assignment.
All patients received a Trilogy DR/DAO (model
2360L or 2364L) or an Integrity AFx (model 5346)
pacemaker (St. Jude Medical, Cardiac Rhythm Manage-
ment Division) combined with existing or newly implanted
market-approved bipolar atrial and ventricular pacing leads.
Devices were programmed to DDDR pacing with a base
rate of 60 ppm randomized to the AF Suppression Algo-
rithm on (treatment group) or off (control group). The
algorithm increased the pacing rate when two intrinsic atrial
events were detected within 16 cycles. Four discrete pro-
grammable algorithm components controlled the overdrive
pacing rate, the duration of overdrive pacing, and the rate at
which the pacing rate decreases after an episode of overdrive
pacing. The lower rate overdrive (LRO) defined the number
of beats/min that the algorithm increased the pacing rate if
the intrinsic rate was between 45 and 59 beats/min. Upper
rate overdrive (URO) determined the number of beats/min
that the algorithm increased the paced rate when the
intrinsic rate exceeded 150 beats/min. The increase in
overdrive rate between LRO and URO was based on a
sliding scale between these two. Once stable pacing was
achieved, the system continued to pace at the overdrive rate
for a programmable number of cycles. If, during a period of
overdrive pacing, additional intrinsic P waves were detected,
the algorithm increased the pacing rate again. If no intrinsic
P waves were detected during the overdrive pacing period,
the algorithm progressively extended the interval between
successive atrial paced complexes, gradually slowing the
effective pacing rate to either the programmed base rate or
the sensor-defined rate. The recovery rate was the fourth
parameter in the algorithm. It defined the cycle length
increase on successive cycles. Two values were provided,
separated by a colon. The first and second values identified
the millisecond increase in cycle length, when the pacing
rate was above and below 100 ppm, respectively. Program-
ming of these components was stipulated for patients in the
treatment group.
Before hospital discharge, each patient received a cardiac
event recorder (Card Guard model 2206 or equivalent; Card
Guard Scientific Survival, Rehovot, Israel) and was in-
structed in its use. Patients were asked to record every
symptomatic episode during the six months following pace-
maker implantation. Follow-up visits were scheduled for 30
days, 90 days, 6 months, 9 months, and 12 months post-
implant, and every 6 months thereafter. In addition to standard
pacemaker follow-up procedures, the following data were
collected: 1) SF-36 Health Survey: patients were asked to
complete the questionnaire before interacting with healthcare
personnel; 2) pacemaker diagnostic data, including the per-
centage of atrial paced beats; 3) antiarrhythmic drug therapy at
implant and changes during follow-up; and 4) information
regarding hospitalizations and cardioversions.
ECG collection and classification. Electrocardiograms
collected from patient-initiated cardiac event recordings of
symptomatic episodes constituted the entire record of AF
episodes in the study. Patients were instructed to transmit
ECGs via telephone to a central receiving center. Two
cardiac electrophysiologists reviewed and classified each
rhythm. The reviewers were blinded to therapy and classi-
fied the rhythms independently. Periodic meetings were
held to resolve any disagreements. A third cardiologist
participated in the review and discussion of any classification
discrepancies between the two primary readers.
End points. The primary end points of the study were
symptomatic AF burden and adverse events. Atrial fibrilla-
tion burden was defined as the total number of AF days
divided by the cumulative follow-up days. An AF day was
one during which a patient transmitted a recording classified
as AF. Atrial fibrillation burden was chosen (rather than
time to first symptomatic AF episode or time between AF
episodes) because it provides information about the fre-
quency of symptomatic AF during the entire follow-up
period. Episodes were documented by event recorders. The
number and duration of the mode-switch episodes were not
utilized as end points in this study because of a lack of direct
ECG correlation with the reported mode-switch episodes
precluding accurate identification of atrial fibrillation epi-
Abbreviations and Acronyms
ADOPT  Atrial Dynamic Overdrive Pacing Trial
AF  atrial fibrillation
ECG  electrocardiogram
LRO  lower rate overdrive
URO  upper rate overdrive
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sodes. Secondary end points included the number of symp-
tomatic AF episodes, hospitalizations, cardioversions, and
quality of life.
Statistical methods. Statistical calculations were made us-
ing the SAS (SAS Institute Inc., Cary, North Carolina),
S-Plus (S-Plus Insightful Corporation, Seattle, Washing-
ton), and BUGS (MRC Biostatistics Unit, Cambridge,
United Kingdom) statistical packages, and all analyses were
based on an intention to treat principle. The sample size was
based on determining whether, during the first six months
of follow-up, patients treated with DDDR pacing with the
algorithm on would have at least a 30% decrease in AF
episodes versus patients treated with DDDR pacing alone.
The log likelihood test using Poisson distribution resulted
in 104 patients per arm at 5% significance level and 80%
statistical power. Therefore, analysis of secondary end
points may lack the requisite statistical power to detect
differences between the treatment groups.
Homogeneity of the treatment groups was assessed by
comparing demographic and baseline characteristics, with
continuous variables summarized by their mean, standard
deviation, minimum and maximum, and categorical vari-
ables summarized through frequency or percent. The pri-
mary efficacy end point was analyzed using the statistical
method for extended generalized linear models based on a
binomial specification (6). The statistical analysis of overall
improvement of the treatment was based on the data
collected at the time points of 30 days, 90 days, and 6
months when patients were scheduled for follow-up visits.
By using these time points, direct correlations could be
made to secondary end points (i.e., quality of life). Other
end points including number of AF episodes, hospitaliza-
tion, cardioversion, adverse events, and automatic mode
switching were also analyzed. For continuous variables,
comparisons were evaluated for significance with the use of
the Wilcox rank-sum test. For categorical end points, a
chi-square test was used to compare the two treatment
groups. Survival was evaluated by the Kaplan-Meier method
along with the log-rank test.
RESULTS
A total of 319 patients (163 men and 156 women) with a
mean age of 71.3  9.9 years were enrolled in the study and
completed 6 months follow-up. Of these, 288 (158 control
and 130 treatment) were included in the analysis. Reasons
for not including patients were all prospective and included
26 whose devices were programmed incorrectly at implant,
4 who were unable to demonstrate ability to use the event
recorder by recording a baseline ECG, and 1 in whom the
investigator could not implant the atrial lead.
There were no significant differences in baseline charac-
teristics between the treatment group and the control group
(Table 1). Antiarrhythmic drugs used in both groups were
similar at baseline and during follow-up (Table 2 and Table
3). Based on pacemaker diagnostic data, the treatment
group experienced a significantly higher percentage of atrial
pacing (mean of 92.9% vs. 67.9%; p  0.0001). Lead
function (sensing, impedance, and pacing thresholds were
similar in both groups. Overall, the total patient population
experienced 2,412 episodes of symptomatic atrial arrhyth-
mias during follow-up; 2,180 (90.4%) classified as AF, 110
(4.6%) as atrial flutter, and 122 (5%) as atrial tachycardia.
The AF Suppression Algorithm reduced symptomatic
Table 1. Comparison of Demographic and Diagnostic Variables
Parameter
Control
(n  158)
Treatment
(n  130) p Value
Age, yrs (mean  SD) 71.3  9.4 71.3  10.3 0.9403
Gender (n/%) 0.9641
Male 84/51 79/51
Female 80/49 76/49
LVEF (mean  SD) 0.57  0.13 (n  109) 0.56  0.13 (n  110) 0.6828
NYHA functional class 0.0673
I 105 80
II 43 58
III 10 10
IV 2 0
Not reported 4 7
AF history
No. of documented episodes in 12 weeks
before implant (mean  SD)
3.3  5.7 3.6  9 0.9537
No. of symptomatic episodes in 6 months
before implant (mean  SD)
8.0  4.2 8.2  4.2 0.7790
AF  atrial fibrillation; NYHA  New York Heart Association.
Table 2. Reported Antiarrhythmic Drugs at Baseline
Drug
Classification*
Control
n (%)
Treatment
n (%)
Class I 20 (13.9) 13 (10.7)
Class II 18 (12.5) 20 (16.5)
Class III 77 (53.5) 66 (54.6)
Class IV 12 (8.3) 5 (4.1)
Digoxin 17 (11.8) 17 (14.1)
*Of the 288 patients, 42 (control) and 34 (treatment) (p 0.9583) reported taking no
drugs, whereas others reported taking at least one drug at implant. Drug class
distributions are similar (p  0.5014).
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AF burden from 2.50% in the control group to 1.87% in the
treatment group, a relative difference of 25%. Atrial fibril-
lation burden decreased progressively during the course of
the follow-up period (Fig. 1) in both groups but was lower
in the group with the AF Suppression Algorithm on (p 
0.005) at each follow-up visit. The burden of symptomatic
atrial arrhythmias (defined as AF, atrial flutter, and atrial
tachyarrhythmias) was reduced by 26.5%, from 2.6% in the
control group to 1.9% in the treatment group, and also
decreased progressively over time (p  0.008).
Secondary end points. Symptomatic episodes of AF oc-
curred in 81 patients in the control group and 73 patients in
the treatment group (p  NS). The treatment group
required 63% fewer cardioversions post-implant (13 vs. 4),
although the difference was not significant (p  0.0925).
The difference in hospitalizations between treatment and
control groups in hospitalizations (15 vs. 17, respectively)
was also not significant (p  0.8439). Before randomiza-
tion, patients were asked to recall the number of AF
episodes they had experienced in the six months prior to
enrollment. The mean number of AF episodes during that
time was similar in both groups (8.0  4.2 treatment vs. 8.3
 4.1 control; p  NS). During six months follow-up, the
mean number of symptomatic AF episodes in the control
and treatment groups was 4.3  11.5 and 3.2  8.6,
respectively (p  NS). In both groups, the decrease in
symptomatic AF frequency was significant (p  0.0001).
In general, quality of life scores improved during
follow-up (Table 4) in both patient groups. In comparison
to values at implant (within group), the control group
exhibited significant improvement during follow-up in five
of the eight subscales and in the standardized mental
component scales. The treatment group exhibited signifi-
cant improvement during follow-up in four of eight sub-
scales and both the standardized physical and mental
component scales. The only statistically significant differ-
ence between the control and treatment groups was a higher
social function score in the treatment group at six months.
Adverse events. The incidence of complications, observa-
tions or other reported events was not significantly different
between the treatment and control groups. Lead dislodg-
ment occurred in seven control and six treatment patients.
Pneumothorax occurred in one control and one treatment
patient. Myocardial perforation and system infection oc-
curred in one treatment patient each. The only observation
specifically related to the algorithm was intolerance to high
rate pacing in three patients. There was no difference in the
number of deaths in the treatment and control groups (5 vs.
1, respectively, p 0.11). One patient in both the treatment
and control groups died of heart failure. The remaining
deaths were due to cardiac arrest, respiratory failure, shock
(of undetermined etiology), and unknown cause.
Automatic mode switching. The duration of automatic
mode switching was similar in the control and treatment
groups at each follow up visit (Table 5) and for the duration
of follow up (1,112 h vs. 1,209 h, respectively, p  NS).
Automatic mode switching is not specific for AF because it
may occur after a few premature atrial beats or as the result
of far field R-wave sensing. Furthermore, automatic mode
switching can occur multiple times during a single episode
of AF and is dependent on pacemaker programming that
was not controlled for in this study. Because the trial
Table 3. Changes in Antiarrhythmic Drug Use During Follow-Up
Control
(n)
Treatment
(n) p Value
New drug 22 17 0.6128
Increased dosage 15 15 0.5265
Decreased dosage 3 7 0.3875
Discontinued drug 11 5 0.2435
Figure 1. Reduction in episodes of symptomatic atrial fibrillation (AF). Atrial fibrillation declined in the population as a whole, and slightly more so in
the treatment group. Open bars  control; solid bars  treatment.
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focused on symptomatic AF and because of the nonspecific
nature of automatic mode switching, the latter was not
included as an end point in this trial. Using prospectively
defined rules to minimize inappropriate automatic mode
switching occurrences (eliminating automatic mode switch
events that were1 min in duration and those in which the
peak filtered atrial rate were at or slightly above the atrial
tachycardia detection rate) the mean number of automatic
mode switches/day was 2.5 in the treatment group and 4.8
in the control group (p  0.14).
DISCUSSION
The ADOPT demonstrated that overdrive atrial pacing
with the AF Suppression Algorithm decreases symptomatic
AF burden in patients with sick sinus syndrome and
paroxysmal AF. The study inclusion requirements (two
symptomatic episodes during the month prior to implant
with one episode documented by ECG or rhythm strip)
were similar to those utilized in studies of drugs used to
suppress AF and were used to ensure a sufficient frequency
of the arrhythmia during follow-up to compare treatment
and control groups appropriately.
Development of a pacemaker algorithm to suppress AF
was based on experimental and clinical experience, suggest-
ing that atrial pacing offers a protective effect when com-
pared with ventricular pacing. In previous retrospective and
prospective studies of patients with sinus node dysfunction,
atrial-based pacing (AAI or DDD) has been associated with
Table 4. Mean Comparisons in Quality of Life
AF Suppression Off AF Suppression On
Delta
p Valuen Mean SD n Mean SD
PF
Implant 156 58.28 28.01 126 59.42 26.96 0.732
6-Month 127 60.40 28.22 110 62.28 26.34 0.600
p Value 0.247 0.202 0.666
RP
Implant 156 28.85 37.80 126 31.02 37.20 0.629
6-Month 126 40.48 43.92 110 47.20 42.44 0.235
p Value 0.001* 0.001* 0.389
BP
Implant 155 65.15 27.94 126 68.21 27.59 0.359
6-Month 129 68.47 28.31 112 72.50 25.62 0.251
p Value 0.150 0.032* 0.429
GH
Implant 154 58.52 22.76 124 60.40 19.15 0.462
6-Month 129 58.69 21.58 107 61.61 19.25 0.278
p Value 0.869 0.636 0.500
VT
Implant 156 39.21 24.85 126 41.60 22.31 0.401
6-Month 129 49.52 22.59 109 53.12 21.35 0.211
p Value 0.001* 0.001* 0.270
SF
Implant 156 62.66 27.71 126 67.26 27.56 0.166
6-Month 128 70.80 26.68 112 80.02 19.89 0.003*
p Value 0.002* 0.001* 0.018*
RE
Implant 154 50.00 43.49 125 54.67 43.87 0.375
6-Month 125 64.80 42.19 109 66.06 41.51 0.819
p Value 0.001* 0.122 0.601
MH
Implant 156 71.24 18.63 125 71.84 19.89 0.794
6-Month 129 74.46 16.80 110 76.02 15.37 0.458
p Value 0.044* 0.070† 0.652
PCS
Implant 152 38.96 10.81 122 39.27 9.51 0.804
6-Month 123 39.88 11.40 103 41.52 10.49 0.265
p Value 0.222 0.013* 0.216
MCS
Implant 152 45.17 10.95 122 46.1 11.2 0.483
6-Month 123 48.96 10.01 103 50.75 8.67 0.158
p Value 0.001* 0.001* 0.710
*p  0.05; †p  0.1.
AF  atrial fibrillation; BP  bodily pain; GH  general health; MCS Mental Component Scale; MH  mental health;
PCS  Physical Component Scale; PF  physical functioning; RE  role—emotional; RP  role—physical; SF  social
functioning; VT  vitality.
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a lower incidence of AF (3,7–10). Subsequent studies
revealed that atrial overdrive pacing was likely to be respon-
sible for the protective effect of pacing (11–13). Atrial
overdrive pacing appears to address the fundamental mech-
anisms believed to give rise to AF, effectively controlling
both rate and rhythm. Sufficiently rapid atrial pacing can
eliminate the pauses following ectopic beats, overdrive
ectopy, and reduce the dispersion of refractoriness that are
thought to set the stage for AF.
Despite these reported effects, the evidence that atrial
overdrive pacing decreases AF has been equivocal. A pilot
study demonstrated that overdrive atrial pacing reduced
atrial ectopy but was underpowered to detect a difference in
AF (14). In recent studies, mode switch episodes and
measures of functional status were similar in patients treated
consecutively with standard pacing and overdrive pacing
(15–17). Design differences between these studies and the
current study may account for differences in outcomes. The
sample sizes, the primary end point (mode switch episodes),
the lower percentage of paced beats, the use of continuous
high rate overdrive pacing in one study, and a relatively
short crossover study design may have obscured beneficial
effects of atrial overdrive pacing in these trials. Despite
differences in study design, preliminary results from the
Consistent Atrial Pacing (CAP) and the Prevention by
Overdriving (PROVE) trials indicated that overdrive pacing
reduced the frequency of AF (18,19).
The results of the current study are consistent with
previous studies showing that conventional atrial pacing
(without overdrive suppression) prevents AF in patients
with sick sinus syndrome (3,4). Symptomatic AF burden
decreased, AF episodes occurred less frequently, and several
quality of life measures improved in both groups. Further-
more, ADOPT is the first study to show that symptomatic
AF burden decreases progressively over time with dual-
chamber pacing. The reason for this is unknown but it is
consistent with the hypothesis that pacing or decreasing AF
burden affects the atrial substrate that is responsible for the
arrhythmia.
Whereas standard DDDR pacing decreased the fre-
quency of AF, the AF Suppression Algorithm provided
additional benefit. Differences in secondary end points
(cardioversions and hospitalizations) did not reach statistical
significance, possibly because the study was not sufficiently
powered to do so. The AF suppression algorithm was safe;
there was no difference in morbidity or mortality between
the two groups.
End points. Symptomatic AF burden was chosen as the
primary end point because it provides information regarding
arrhythmia frequency during the entire follow-up period.
Symptomatic AF episodes were used rather than mode
switch episodes to enhance the specificity of the measure.
Mode switching can occur for atrial arrhythmias or signals
other than AF, some of which may be very brief and
clinically insignificant. Whereas this method for determin-
ing AF burden may not account for all AF episodes (an
individual could have more than one episode in a day), it
circumvents the problem of patients who may transmit more
than once during a single episode.
Study limitations. A potential limitation was reliance on
self-reporting by patients; patients determined what consti-
tuted a symptomatic episode, used the event recorder to
record the ECG, and transmitted the resulting ECG.
However, this technique has been used in studies of drugs
for suppression of AF and it has been shown to be effective
in both a meta-analysis (20) and an experimental compar-
ison with Holter recording (21).
The focus on symptomatic AF burden as the primary
measure of the algorithm’s efficacy meant that the sample
size was based exclusively on detecting the reduction in
symptomatic AF episodes. This limits the statistical power
of the secondary analyses. This study was not powered
sufficiently to permit any assessment of the impact of the AF
Suppression Algorithm on the incidence of hospitalizations
or cardioversions in this patient population.
The prospectively defined requirement that pacemakers
be programmed appropriately resulted in the exclusion of 26
patients from the trial, most of whom were in the treatment
group. We cannot exclude the possibility that the exclusion
of these patients increased or decreased the observed treat-
ment effect.
Whereas the absolute AF burden reduction (2.50% to
1.87%) is small, it represents a relative reduction of 25% and
it occurred despite a decrease in AF frequency that occurred
in both the treatment and the control groups. The reduction
in AF frequency in the control group and the incremental
reduction in the treatment group are similar to those
reported for drug therapy to suppress AF. Furthermore, the
reduction occurred in patients, many of whom were receiv-
ing antiarrhythmic drugs.
Conclusions. The ADOPT demonstrates that the AF
Suppression Algorithm is safe and effective in patients with
symptomatic AF and sick sinus syndrome. Given the
apparent safety of the algorithm as it was programmed in
the ADOPT and because it is an incremental therapy that
can be programmed on or off in patients who are receiving
Table 5. Mean Duration of Automatic Mode Switching (h)
Visit
AF
Suppression Off
AF
Suppression On p Value
1-Month
n 145 115
Mean 227 150 0.1968
SD 652 272
3-Month
n 141 117
Mean 362 363 0.9133
SD 565 562
6-Month
n 126 111
Mean 523 697 0.4180
SD 791 1,117
AF  atrial fibrillation.
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a pacemaker for another reason, this therapy offers an
attractive option for patients with the sick sinus syndrome
and AF. The application of this algorithm to other patient
populations requires further studies. This trial supports the
concept that atrial repolarization alters development of AF.
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